Category - Developments

Developments

GT submits IND for GTB-5550 TriKE in solid tumors

GT Biopharma (NASDAQ: GTBP) has announced that it submitted an investigational new drug (IND) application to the FDA in December 2025 for GTB-5550 TriKE, a B7-H3-targeted natural killer (NK) cell engager for the...

January 15, 2026

Developments

Frontiers in Oncology to publish BioMark’s research on ML model for lung cancer detection

BioMark Diagnostics (CSE: BUX; FSE: 20B; OTCQB: BMKDF) has announced that the peer-reviewed journal Frontiers in Oncology has accepted for publication the company’s research on a machine learning (ML) predictive model...

January 15, 2026

Developments

Mount Sinai becomes first in NYC to deliver incision-free, MRI-guided prostate treatment with Profound’s TULSA-PRO

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that the world-renowned Mount Sinai Hospital, Metro New York (NYC), has successfully treated its first prostate cancer patient with the TULSA-PRO system. The TULSA...

January 15, 2026

Developments

cbdMD acquires Bluebird Botanicals

cbdMD (NYSE American: YCBD) has announced the strategic acquisition of closely held Bluebird Botanicals through an asset purchase comprised of an initial share issuance and earnout shares. According to cbdMD, the...

January 14, 2026

Developments

Clearmind achieves 100% treatment success in second cohort of CMND-100 trial in AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100—the...

January 14, 2026

Developments

Profound surpasses 2025 TULSA-PRO installed base goal

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that its TULSA-PRO system installed base reached 78 as of December 31, 2025—exceeding its previously announced goal of 75 installs by year-end 2025. The company’s TULSA...

January 12, 2026

Developments

Nature Eye publishes positive Phase 1 results for Ocugen’s gene therapy

Ocugen (NASDAQ: OCGN) has announced the publication of positive Phase 1 GARDian1 trial results for OCU410ST, its novel modifier gene therapy for Stargardt disease, in the peer-reviewed journal Nature Eye, published by...

January 12, 2026

Developments

PharmaJet’s Needle-free Injection System selected for DNA immunotherapy in advanced melanoma

Closely held PharmaJet announced that its partner, Scancell, has reported updated Phase 2 clinical data from the SCOPE study in unresectable advanced melanoma demonstrating a progression-free survival (PFS) rate of 74%...

January 9, 2026

Developments

Autonomix highlights data showing pain relief observed in all stages of pancreatic cancer

Autonomix Medical (NASDAQ: AMIX) has announced new subgroup clinical data from its proof-of-concept study presented at the 2026 ASCO Gastrointestinal Cancers Symposium demonstrating rapid, durable, and meaningful pain...

January 9, 2026

Developments

Athira announces name change to LeonaBio with new ticker LONA

Athira Pharma (NASDAQ: ATHA) has announced that it has changed its name to LeonaBio (NASDAQ: LONA) effective January 12, 2026, to align with its acquisition of rights to develop and commercialize lasofoxifene, a late...

January 9, 2026

Category - Developments

Subscribe